Singapore markets open in 3 hours 51 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.48-0.02 (-0.16%)
At close: 1:00PM EST
12.59 +0.11 (+0.88%)
After hours: 04:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.50
Bid12.45 x 1200
Ask12.60 x 900
Day's range12.24 - 13.12
52-week range4.74 - 18.48
Avg. volume2,663,926
Market cap2.246B
Beta (5Y monthly)2.49
PE ratio (TTM)N/A
EPS (TTM)-1.27
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.91
  • Motley Fool

    BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript

    Participating with me today are CEO Jon Stonehouse; CFO Anthony Doyle; Chief Commercial Officer Charlie Gayer; Chief Medical Officer Dr. Three quarters of the way into 2021, and this has been an amazing year of execution for our company.

  • Motley Fool

    Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today

    Shares of BioCryst (NASDAQ: BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. The FDA approved BioCryst's first drug, Orladeyo, for patients with hereditary angioedema last December. Independent new drug launches have a terrible tendency to miss expectations, so the stock market is extra jumpy about revenue figures right now.

  • Zacks

    BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?